IN2014DN08653A - - Google Patents

Info

Publication number
IN2014DN08653A
IN2014DN08653A IN8653DEN2014A IN2014DN08653A IN 2014DN08653 A IN2014DN08653 A IN 2014DN08653A IN 8653DEN2014 A IN8653DEN2014 A IN 8653DEN2014A IN 2014DN08653 A IN2014DN08653 A IN 2014DN08653A
Authority
IN
India
Prior art keywords
group
hydrogen atom
formula
provides
present
Prior art date
Application number
Inventor
Tatsuya Nishi
Naoki Tanaka
Ryoko Kitazawa
Riki Goto
Takashi Ishiyama
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2014DN08653A publication Critical patent/IN2014DN08653A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1) or the like. (In the formula R represents an aromatic hydrocarbon ring group or an aromatic heterocyclic group; R represents a hydrogen atom an alkyl group or a heterocycloalkyl group; R represents a hydrogen atom or an alkyl group; A represents a hydrogen atom or a hydroxyl group; L represents NHCO or OCH ; and X represents a nitrogen atom or =CH .)
IN8653DEN2014 2012-03-30 2013-03-29 IN2014DN08653A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012079859 2012-03-30
PCT/JP2013/059657 WO2013147216A1 (en) 2012-03-30 2013-03-29 (2-heteroarylamino)succinic acid derivative

Publications (1)

Publication Number Publication Date
IN2014DN08653A true IN2014DN08653A (en) 2015-05-22

Family

ID=49260457

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8653DEN2014 IN2014DN08653A (en) 2012-03-30 2013-03-29

Country Status (11)

Country Link
US (1) US9206168B2 (en)
EP (1) EP2832726B1 (en)
JP (1) JP6100755B2 (en)
KR (1) KR20140147825A (en)
CN (1) CN104334528A (en)
CA (1) CA2869135A1 (en)
ES (1) ES2649905T3 (en)
HK (1) HK1204622A1 (en)
IN (1) IN2014DN08653A (en)
TW (1) TW201400458A (en)
WO (1) WO2013147216A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9634549B2 (en) 2013-10-31 2017-04-25 General Electric Company Dual phase magnetic material component and method of forming
TWI773657B (en) 2015-12-18 2022-08-11 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
WO2021003295A1 (en) * 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
CN111559982B (en) * 2020-06-09 2023-04-07 天津市医药科学研究所 2- (2-substituted-4-hydroxypyrimidine-5-formamido) acetic acid compound and preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040106A2 (en) * 1998-02-09 1999-08-12 University Of Southern California Use of angiotensin analogues for promoting erythropoiesis
IL163711A0 (en) * 2002-03-08 2005-12-18 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
CN101849943A (en) * 2005-06-06 2010-10-06 菲布罗根公司 Use the improved treatment for anemia of HIF alpha stabilizers
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
ES2524883T3 (en) 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hydroxypyrimidine-5-substituted carboxamides
AP2014007897A0 (en) * 2008-04-01 2014-08-31 Weir Minerals Australia Ltd A lifter bar assembly for a crushing mill and method of installation
TW200948788A (en) * 2008-04-22 2009-12-01 Daiichi Sankyo Co Ltd 5-hydroxypyrimidine-4-carboxamide compounds
WO2011002623A1 (en) 2009-06-30 2011-01-06 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
CN102802628A (en) 2009-06-30 2012-11-28 默沙东公司 Substituted 4-hydroxypyrimidine-5-carboxamides
JP2011088840A (en) * 2009-10-21 2011-05-06 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising 5-hydroxypyrimidine-4-carboxamide compound
PL2492266T3 (en) * 2009-10-21 2016-01-29 Daiichi Sankyo Co Ltd 5-hydroxypyrimidine-4-carboxamide derivative
JP2011105708A (en) * 2009-10-21 2011-06-02 Daiichi Sankyo Co Ltd Pharmaceutical composition containing 5-hydroxypyrimidine-4-carboxamide compound
TWI412114B (en) * 2009-12-31 2013-10-11 Advanced Semiconductor Eng Semiconductor package and method for making the same
WO2011132633A1 (en) * 2010-04-19 2011-10-27 第一三共株式会社 Substituted 5-hydroxypyrimidine-4-carboxamide compound

Also Published As

Publication number Publication date
EP2832726B1 (en) 2017-09-06
US9206168B2 (en) 2015-12-08
US20150011574A1 (en) 2015-01-08
EP2832726A4 (en) 2015-12-02
HK1204622A1 (en) 2015-11-27
CA2869135A1 (en) 2013-10-03
CN104334528A (en) 2015-02-04
EP2832726A1 (en) 2015-02-04
WO2013147216A1 (en) 2013-10-03
KR20140147825A (en) 2014-12-30
ES2649905T3 (en) 2018-01-16
JP6100755B2 (en) 2017-03-22
TW201400458A (en) 2014-01-01
JPWO2013147216A1 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
IN2014MN02574A (en)
PH12015500263A1 (en) New bicyclic derivatives
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
TN2012000575A1 (en) Compositions and methods for modulating the wnt signaling pathway
WO2014008458A3 (en) N-substituted benzamides and methods of use thereof
IN2014MN02244A (en)
MX2013006585A (en) Indeno-fused ring compounds.
IN2014MN02211A (en)
CR20140306A (en) FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES
MX2014014531A (en) Aminoquinazoline and pyridopyrimidine derivatives.
MY169267A (en) New aryl-quinoline derivatives
MX346746B (en) Indeno- fused ring compounds having photochromic properties.
MX2015001099A (en) New bicyclicpyridine derivatives.
AU2013348091A8 (en) Synthesis of spirocyclic isoxazoline derivatives
IN2014DN08653A (en)
UA111950C2 (en) HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NERROTRANSMISSION OF SEROTONIN, NOREPINEPHIN OR DOPIN
MX369470B (en) Means and method for treating solid tumours.
MX355415B (en) Compositions and methods for modulating a kinase.
IN2015DN02588A (en)
CO6660459A2 (en) 4- (Methylaminophenoxy) pyridin-3-yl-benzamine derivatives to treat cancer
SE1100784A1 (en) New phosphate compound
MX2013009388A (en) New azaspirodecanone compounds as hsl inhibitors.
MX346980B (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds.
IN2015DN02514A (en)
MX2015006828A (en) Method for producing 4-haloalkyl -3-mercapto-substituted 2-hydroxy-benzoic acid derivatives.